The life of a drug is short. Make every day count.

In the coming years, Bristol Myers Squibb, Merck, Amgen, Novartis, and AstraZeneca will experience the highest level of exposure to generic and biosimilar competition, while Vertex, Gilead Sciences, Sanofi, Novo Nordisk, and Eli Lilly will be the least exposed over the 2025-2030 timeframe.

From 2030 onward, however, Lilly, Gilead, and Novo are much more likely to take a hit from LOEs alongside companies like Regeneron and Biogen. Vertex, GSK, Pfizer, Takeda, and Amgen are likely to fare the best in terms of LOE exposure from 2030 through 2040.

Naturally, companies are eagerly looking to acquire external high rNPV products with the potential to launch in the near term in addition to bolstering their internal R&D pipelines.

The hunt for the next generation of blockbusters is on; JPM2025 promises to be fun!

Yet, not every blockbuster hopeful will make it to the finish line. It would be okay if the only reason science-based products did not reach their expected potential were because of the biological variables.

Today, with the ability to anticipate challenges, plan for alternative scenarios in approvals, reimbursements, and launches, and make predictive decisions to navigate future obstacles, operational variables should no longer limit the potential of years of R&D.

Patients should not miss out on timely access to medicines due to preventable delays.

Takeaway: The life of a drug is short; make every day count!